Analyst: 'Mess Continues' With Amgen Neupogen Competitor

By: via Benzinga
Amgen, Inc. (NASDAQ: AMGN) will face competition for its Neupogen chemotherapy treatment from biotechnology, but exactly when a newly ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.